Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
1.2.1. Ulcerative Colitis Market, by Region, 2019-2027 (USD Billion)
1.2.2. Ulcerative Colitis Market, by Drug, 2019-2027 (USD Billion)
1.2.3. Ulcerative Colitis Market, by Disease, 2019-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Ulcerative Colitis Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Ulcerative Colitis Market Dynamics
3.1. Ulcerative Colitis Market Impact Analysis (2019-2027)
3.1.1. Market Drivers
3.1.1.1. Increase in patient assistance programs
3.1.1.2. Growing incidence and prevalence of Ulcerative Colitis
3.1.2. Market Restraint
3.1.2.1. Side-effects of medications
3.1.2.2. High levels of unmet clinical need in Ulcerative Colitis
3.1.3. Market Opportunities
3.1.3.1. Huge R&D and investment done by key players
Chapter 4. Global Ulcerative Colitis Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Ulcerative Colitis Market, by Drug
5.1. Market Snapshot
5.2. Global Ulcerative Colitis Market by Drug, Performance - Potential Analysis
5.3. Global Ulcerative Colitis Market Estimates & Forecasts by Drug 2018-2027 (USD Billion)
5.4. Ulcerative Colitis Market , Sub Segment Analysis
5.4.1. Anti-Inflammatory Drugs
5.4.2. Anti-TNF biologics
5.4.3. Immunosuppressant
5.4.4. Calcineurin Inhibitors
5.4.5. Other Drug Types
Chapter 6. Global Ulcerative Colitis Market, by Disease
6.1. Market Snapshot
6.2. Global Ulcerative Colitis Market by Disease, Performance - Potential Analysis
6.3. Global Ulcerative Colitis Market Estimates & Forecasts by Disease 2018-2027 (USD Billion)
6.4. Ulcerative Colitis Market , Sub Segment Analysis
6.4.1. Ulcerative Proctitis
6.4.2. Proctosigmoiditis
6.4.3. Left-sided Colitis
6.4.4. Pancolitis or Universal Colitis
6.4.5. Fulminant Colitis
Chapter 7. Global Ulcerative Colitis Market, Regional Analysis
7.1. Ulcerative Colitis Market , Regional Market Snapshot
7.2. North America Ulcerative Colitis Market
7.2.1. U.S. Ulcerative Colitis Market
7.2.1.1. Drug breakdown estimates & forecasts, 2018-2027
7.2.1.2. Disease breakdown estimates & forecasts, 2018-2027
7.2.2. Canada Ulcerative Colitis Market
7.3. Europe Ulcerative Colitis Market Snapshot
7.3.1. U.K. Ulcerative Colitis Market
7.3.2. Germany Ulcerative Colitis Market
7.3.3. France Ulcerative Colitis Market
7.3.4. Spain Ulcerative Colitis Market
7.3.5. Italy Ulcerative Colitis Market
7.3.6. Rest of Europe Ulcerative Colitis Market
7.4. Asia-Pacific Ulcerative Colitis Market Snapshot
7.4.1. China Ulcerative Colitis Market
7.4.2. India Ulcerative Colitis Market
7.4.3. Japan Ulcerative Colitis Market
7.4.4. Australia Ulcerative Colitis Market
7.4.5. South Korea Ulcerative Colitis Market
7.4.6. Rest of Asia Pacific Ulcerative Colitis Market
7.5. Latin America Ulcerative Colitis Market Snapshot
7.5.1. Brazil Ulcerative Colitis Market
7.5.2. Mexico Ulcerative Colitis Market
7.6. Rest of The World Ulcerative Colitis Market
Chapter 8. Competitive Intelligence
8.1. Top Market Strategies
8.2. Company Profiles
8.2.1. Takeda Pharmaceutical Company Limited
8.2.1.1. Key Information
8.2.1.2. Overview
8.2.1.3. Financial (Subject to Data Availability)
8.2.1.4. Product Summary
8.2.1.5. Recent Developments
8.2.2. AbbVie Inc. (Allergan, Inc.)
8.2.3. Boehringer Ingelheim GmbH
8.2.4. Bausch Health Companies Inc.
8.2.5. Johnson and Johnson
8.2.6. Teva Pharmaceutical Industries Ltd
8.2.7. Eli Lilly and Company
8.2.8. Bridge Biotherapeutics, Inc.
8.2.9. Pfizer Inc.
8.2.10. Arena Pharmaceuticals, Inc.
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption